By Stephen Nakrosis Ortho Clinical Diagnostics Holdings PLC on Friday said its Vitros Anti-SARS-CoV-2 IgG Quantitative Test became the first quantitative Covid-19 IgG antibody test to receive an emergency use authorization from the U.S. Food and Drug Administration. Ortho said the test targets the S1 spike protein and is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2. The company also said the test is calibrated to the World Health Organization International Standard for anti-SARS-CoV-2 IgG antibodies. Ivan Salgo, the company s head of medical, clinical, and scientific affairs, said, Ortho s quantitative Covid-19 IgG antibody test, which targets the spike protein, is an important tool to help health care and policy teams to understand long-term antibody responses to SARS-CoV-2.
Buy These 31 Stocks With Average 30% Upside; BofA s Best Ideas for 2H businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
Operator
Good day, and thank you for standing by. Welcome to the Ortho Clinical Diagnostics quarter one 2021 earnings conference call. [Operator instructions] I would now like to hand the conference over to your first our first speaker for today, Mr. John Sanders, vice president of finance, treasurer, and head of investor relations.
Thank you. Please go ahead.
John Sanders
Vice President of Finance, Treasurer, and Head of Investor Relations
Thank you, Ann. And good afternoon, everyone. With me today to discuss our financial results are the chairman and CEO of Ortho Clinical Diagnostics, Chris Smith; and Joe Busky, Ortho s chief financial officer; Mike Iskra, our EVP of commercial excellence and strategy, will join us on the Q&A portion of the call. This conference call is being simultaneously webcast on the Investors section of our website, and a version of today s presentation can be downloaded there.
Amgen (AMGN)
In a report released yesterday, Brian Skorney from Robert W. Baird reiterated a Sell rating on Amgen, with a price target of $185.00. The company’s shares closed last Wednesday at $236.71.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 5.8% and a 51.1% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Intellia Therapeutics.
Amgen has an analyst consensus of Moderate Buy, with a price target consensus of $250.24, which is a 3.6% upside from current levels. In a report released yesterday, Atlantic Equities also downgraded the stock to Sell with a $200.00 price target.
Allogene Therapeutics (ALLO)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Allogene Therapeutics, with a price target of $43.00. The company’s shares closed last Wednesday at $35.12.
According to TipRanks.com, Burns is a 4-star analyst with an average return of 15.5% and a 44.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Allogene Therapeutics with a $46.50 average price target, implying a 42.8% upside from current levels. In a report issued on April 12, Oppenheimer also assigned a Buy rating to the stock with a $52.00 price target.